tomopenem

A 1-beta-methylcarbapenem antibiotic with broad-spectrum activity against gram-positive and gram-negative bacteria. Tomopenem has a longer half-life… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2017
02420082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objectives; Tomopenem (CS-023) is a novel parenteral carbapenem with broad spectrum activity against Gram-positive and -negative… (More)
  • figure 2
  • table 1
  • table 2
Is this relevant?
2011
2011
Tomopenem (formerly CS-023) is a novel carbapenem with improved activity against diverse hospital pathogens, including… (More)
Is this relevant?
2010
2010
Tomopenem (formerly CS-023) is a novel carbapenem with broad-spectrum activities against diverse hospital pathogens, including… (More)
Is this relevant?
2010
2010
The postantibiotic effect (PAE) of tomopenem was determined after a 2 h exposure of two strains of meticillin-susceptible and… (More)
Is this relevant?
2009
2009
The antianaerobic activity of tomopenem, a new longer-half-life parenteral carbapenem, was compared with other carbapenems… (More)
  • table 1
  • table 2
  • table 2
Is this relevant?
2009
2009
Tomopenem (formerly CS-023), a novel 1beta-methylcarbapenem, exhibited high affinity for penicillin-binding protein (PBP) 2 in… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2008
2008
Tomopenem (formerly CS-023) is a novel 1beta-methylcarbapenem with broad-spectrum coverage of gram-positive and gram-negative… (More)
  • table 2
  • table 1
  • figure 2
  • table 3
Is this relevant?
2008
2008
The antibacterial effects (ABE) of tomopenem (formerly RO4908463/CS-023) against seven Staphylococcus aureus strains (methicillin… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 6
Is this relevant?
2008
2008
OBJECTIVES Tomopenem (CS-023) is a novel parenteral carbapenem with broad-spectrum activity against Gram-positive and -negative… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2008
2008
The objective of this study was to assess the impact of impaired renal function on the pharmacokinetics of tomopenem (RO4908463… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?